• Zehra Batool

ABSTRACT Polymeric nanoparticles are a promising novel drug delivery system and have advantages in abnormal lipids therapy. Fenofibrate is Hypolipidemic Agent that is used in the treatment of a variety of cardiovascular disease in those at high risk and treats abnormal blood lipid levels. It is recommended to be used together with dietary changes, exercise, and weight loss. The aim of the present study was to prepare and evaluate novel polymeric nanoparticles containing Fenofibrate. The objective of the present study was to formulate and evaluate polymeric nanoparticles of Fenofibrate by Emulsification sonication method using Sodium alginate, Chitosan and Ethyl cellulose as a polymer. The nanoparticles were characterized for FTIR, particle size, poly-dispersity index, entrapment efficiency (EE), zeta potential, morphological study, differential scanning calorimetry (DSC) and invitro study. Infrared studies showed that there was no drug excipients interaction. Negative values of zetapotential indicated the good stabilization of the prepared nanoparticles. Nine formulations of Fenofibrate nanoparticles were prepared using Emulsification sonication method. The particles sizes and zeta potential were measured using zeta-plus analyzer. The particle morphology was also studied using scanning electron microscopy (SEM). The in-vitro release of the drug from the nanoparticles was carried out in phosphate buffer saline pH 6.8. The particle sizes of the prepared nanoparticles were in nano size which ranged from (140.5 to 173.9nm) with positive zeta potential. The drug entrapment efficiency was varied with the drug polymer ratio from 51.82% to 75.14%. The SEM showed uniform shape and regularly distributed particle sizes. The in-vitro drug release study exhibited the sustained release of Fenofibrate with burst release. The cumulative percentage released after 12 hr. were between were 72.34 and 98.76%. The studies, therefore, indicate the successful formulation development of nanoparticles with distinctly improved bioavailability potential and can be used as drug carrier for sustained or prolonged drug release.

Clonidine HCL ,Fenofibrate, Emulsification sonication method, odium alginate, Chitosan, Ethyl cellulose and Nanoparticles.

"Formulation and characterization of transdermal drug delivery system of clonidine HCL for the treatment of hypertension.", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 12, page no.h924-h962, December-2024, Available :http://www.jetir.org/papers/JETIRTHE2165.pdf

"Formulation and characterization of transdermal drug delivery system of clonidine HCL for the treatment of hypertension.", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 12, page no. pph924-h962, December-2024, Available at : http://www.jetir.org/papers/JETIRTHE2165.pdf